Description of a pediatric case of sickle-cell anemia treated with hydroxyurea

• Autores: Gonzalo González Morcillo, Juan Manuel Rodríguez Camacho, Aina Oliver Noguera
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 21, Nº. 3, 2019, págs. 167-169
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Sickle cell syndrome (SCD) is a disease characterized by a structural change of hemoglobin that leads to a structural and functional alteration of the erythro cytes causing varied symptomatology, with vaso-occlusive phenomena being the most characteristic manifestation. Hidroxyurea (HU) is the only drug approved in Europe for the prevention of vaso-occlusive crises in infants. ,its efficacy and safety has been demonstrated in several clinical trials, however it has not been widely used in clinical practice probably due to its lack of evidence in long-term therapy. It is reported the case of a 19-month-old patient diagnosed with SCD at six months of age and who is treated with HU after several vaso-occlusive episodes. Eight months after starting treatment, there was a reduction in the number of hospital admissions for the patient and an improvement in the hemoglobin levels, without adverse effects that would lead to discontinuation of the treatment. In our experience, HU was an effective and safe drug to treat SCD in a pediatric patient